


**AstraZeneca Pharmaceuticals LP**  
Docket No. **Z70402-1/US**  
**Page 5**

Support for new Claims 12-17 is found in original Claims 7-11 and throughout the specification. Differences between the old and new claims are merely the result of the Applicant's desire to remove multiple dependencies.

Applicant believes that no fee is due for this Preliminary Amendment. But, if a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 26-0166 for the required amount.

Respectfully submitted  
AstraZeneca



Dated: 30 March 2001

---

Richard V. Person, Ph.D.  
Attorney for Applicants  
Reg. No. 42,991  
Telephone: 302/886-7429

**Version with marking to show changes made**

7. (Amended) A compound according to ~~any~~ of Claims 2, 3, 4, ~~or~~ 6, wherein:

$R^3$  is hydrogen, methyl or ethyl;

$R^4$  is  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkyl, halogen, halo $C_{1-2}$ alkoxy, halo $C_{1-4}$ alkyl,  $-CH=CHCH_3$ ,

$-S(O)_nCH_3$ , or  $-OS(O)_2CH_3$ ;

$R^5$  is cyano, nitrogen, hydrogen or halogen;

$R^6$  is hydrogen, methoxy, cyano or nitro; and

$n$  is 0, 1 or 2.